GSK-217744/078 (DTPa-HBV-IPV-078)

An open, multicentre, phase IV clinical trial to assess the immunogenicity and reactogenicity of GSK Biologicals’ combined DTPa-HBV-IPV/Hib vaccine, when co-administered at 3-4-5 Mth of age with Wyeth-Lederle's seven-valent pneumococcal conjugate vaccine at a different injection site during the same visit
Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine
217744/078 (DTPa-HBV-IPV-078)
Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus
Phase 4
An annotated case report form is not available for this study. A blank case report form will be provided. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
September 2013